Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
December 17, 2021 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Third Quarter 2021 Financial Results
December 09, 2021 07:00 ET
|
Entrada Therapeutics, Inc.
Successful completion of upsized $208.7 million Initial Public Offering BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company...
Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
November 18, 2021 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular...
Entrada Therapeutics Announces Closing of Initial Public Offering
November 02, 2021 16:26 ET
|
Entrada Therapeutics, Inc.
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™)...
Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering
October 28, 2021 22:21 ET
|
Entrada Therapeutics, Inc.
BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™)...